Tania Ochi Lohmann

2.1k total citations · 1 hit paper
5 papers, 1.2k citations indexed

About

Tania Ochi Lohmann is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Psychiatry and Mental health. According to data from OpenAlex, Tania Ochi Lohmann has authored 5 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 1 paper in Psychiatry and Mental health. Recurrent topics in Tania Ochi Lohmann's work include Lung Cancer Treatments and Mutations (4 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Lung Cancer Research Studies (2 papers). Tania Ochi Lohmann is often cited by papers focused on Lung Cancer Treatments and Mutations (4 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Lung Cancer Research Studies (2 papers). Tania Ochi Lohmann collaborates with scholars based in Switzerland, United Kingdom and United States. Tania Ochi Lohmann's co-authors include Michael McCleod, Marcin Kowanetz, Howard West, Federico Cappuzzo, Achim Rittmeyer, Davey B. Daniel, Niels Reinmuth, Hans‐Georg Kopp, Maen Hussein and Tarek Mekhail and has published in prestigious journals such as Cancer Research, The Lancet Oncology and Annals of Oncology.

In The Last Decade

Tania Ochi Lohmann

5 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

2019 1.1k citations Howard West, Michael McCleod et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tania Ochi Lohmann Switzerland	4	1.1k	836	193	110	89	5	1.2k
Jerónimo Rafael Rodríguez‐Cid Mexico	9	970 0.9×	746 0.9×	130 0.7×	75 0.7×	86 1.0×	31	1.1k
Marco Angelo Burgio Italy	15	676 0.6×	513 0.6×	138 0.7×	115 1.0×	152 1.7×	44	883
Esther Holgado Spain	15	757 0.7×	367 0.4×	207 1.1×	169 1.5×	129 1.4×	42	870
Peijian Peng China	14	558 0.5×	385 0.5×	142 0.7×	152 1.4×	183 2.1×	26	834
Allen C. Chen United States	10	745 0.7×	395 0.5×	283 1.5×	68 0.6×	91 1.0×	13	850
Santiago Ponce Aix Spain	15	620 0.6×	406 0.5×	150 0.8×	81 0.7×	165 1.9×	92	828
J.M. Sánchez-Torres Spain	13	614 0.6×	428 0.5×	99 0.5×	104 0.9×	150 1.7×	21	772
Jinpeng Shi China	13	566 0.5×	446 0.5×	141 0.7×	169 1.5×	261 2.9×	27	840
Norikazu Matsuo Japan	14	442 0.4×	376 0.4×	153 0.8×	76 0.7×	95 1.1×	40	677
Bernadette Reyna Asuncion United States	9	425 0.4×	301 0.4×	180 0.9×	98 0.9×	147 1.7×	16	658

Countries citing papers authored by Tania Ochi Lohmann

Since Specialization

Citations

This map shows the geographic impact of Tania Ochi Lohmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tania Ochi Lohmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tania Ochi Lohmann more than expected).

Fields of papers citing papers by Tania Ochi Lohmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tania Ochi Lohmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tania Ochi Lohmann. The network helps show where Tania Ochi Lohmann may publish in the future.

Co-authorship network of co-authors of Tania Ochi Lohmann

This figure shows the co-authorship network connecting the top 25 collaborators of Tania Ochi Lohmann. A scholar is included among the top collaborators of Tania Ochi Lohmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tania Ochi Lohmann. Tania Ochi Lohmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Solomon, Benjamin, Jin Seok Ahn, Rafał Dziadziuszko, et al.. (2023). LBA2 ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC). Annals of Oncology. 34. S1295–S1296. 38 indexed citations

2.

West, Howard, Michael McCleod, Maen Hussein, et al.. (2019). Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology. 20(7). 924–937. 1137 indexed citations breakdown →

3.

West, Howard, Michael McCleod, Maen Hussein, et al.. (2019). Abstract CT200: IMpower130: Progression-free survival (PFS) and safety analysis from a randomized phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab as first-line (1L) therapy in advanced non-squamous NSCLC. Cancer Research. 79(13_Supplement). CT200–CT200. 2 indexed citations

4.

Cappuzzo, Federico, Michael McCleod, Maen Hussein, et al.. (2018). IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. Annals of Oncology. 29. viii742–viii743. 46 indexed citations

5.

Arango, Celso, Henry A. Nasrallah, Stephen M. Lawrie, et al.. (2014). Efficacy and safety of adjunctive bitopertin (5 and 10mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics — Results from the phase III DayLyte study. Schizophrenia Research. 158(1-3). e1–e1. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact